Navigation Links
Cepheid Welcomes Senior Vice President of Human Resources

SUNNYVALE, Calif., Jan. 17, 2012 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced that it has appointed Mr. Mike Fitzgerald to the position of Senior Vice President, Human Resources, effective January 14, 2012. 

Mr. Fitzgerald joins Cepheid from Verigy, Inc., a wholly owned subsidiary of Advantest Corp., where he most recently served as Senior Vice President of Human Resources.  Prior to Verigy, Mr. Fitzgerald was Vice President of Human Resources at Varian, Inc. where he was responsible for the development and implementation of a global human resources program in support of the company's corporate goals for approximately 3,500 employees worldwide.  In total, Mr. Fitzgerald brings more than two decades of broad human resources experience to Cepheid, including Vodafone, PLC, and Xerox Financial Services.

In connection with his employment, the Compensation Committee of Cepheid's Board of Directors has granted Mr. Fitzgerald an option to purchase 56,000 shares of Cepheid common stock at the closing price of Cepheid common stock on Mr. Fitzgerald's employment commencement date and restricted stock units in respect of 10,000 shares of Cepheid common stock.  The option will become exercisable by Mr. Fitzgerald over four years, with 25% vesting on the one-year anniversary of grant and ratably monthly thereafter, and will expire after seven years from the grant date, so long as Mr. Fitzgerald continues to be employed or provide services to Cepheid.  The restricted stock units will become exercisable by Mr. Fitzgerald over four years, with 25% vesting on the one-year anniversary of the grant and as to an additional 1/16th of the restricted stock units at the end of each three-month period thereafter, so long as Mr. Fitzgerald continues to be employed or provide services to Cepheid.  The option and restricted stock units were granted as inducement grants pursuant to Section 5635(c)(4) of The NASDAQ Stock Market Rules.

About CepheidBased in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests.  By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases.  Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit

CONTACTS:For Media Inquiries:For Investor Inquiries:Jared Tipton

Jacquie RossCepheid Corporate Communications

Cepheid Investor RelationsTel: (408) 400 8377

Tel: (408) 400" target="_blank">


SOURCE Cepheid
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Receives FDA Clearance for Xpert Flu, Delivering Simultaneous Detection and Differentiation of Flu A, Flu B, and 2009 H1N1 Strain
2. Cepheid Schedules 2010 Third Quarter Financial Results Announcement and Webcast
3. Cepheid to Webcast Upcoming Financial Presentations
4. Cepheid Expands Leadership Team With Appointment of Executive Vice President of Worldwide Commercial Operations
5. Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast
6. Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast
7. Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
8. Cepheid Reports 2009 First Quarter Results
9. Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast
10. Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB)
11. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
Post Your Comments:
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... 2016 Andrew D ... Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology:
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
Breaking Biology News(10 mins):